Diffuse large B‐cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome
- 7 March 2011
- journal article
- research article
- Published by Wiley in Hematological Oncology
- Vol. 29 (1), 38-41
- https://doi.org/10.1002/hon.953
Abstract
Bone marrow (BM) involvement in diffuse large B‐cell lymphoma (DLBCL) can be morphologically discordant from the primary tumor. Concordant BM infiltration has been shown associated with a poorer outcome in patients treated with CHOP. In order to evaluate tumor‐related factors leading to BM involvement in DLBCL, we performed an integrated analysis of i) genomic profiles obtained with a high‐density genome wide SNP‐based arrays ii) immunomorphological and iii) clinical data from 133 patients uniformly treated with R‐CHOP. BM infiltration was found in 27 of 133 (20%) cases; and it was concordant in 18/27 (67%) cases. Concordant infiltration, but not discordant, influenced negatively OS, PFS and DFS and was associated with higher serum LDH, lower CR and higher PD rates. No association with cell of origin was found between BM+ and BM‐ DLBCL. As compared with BM‐ cases, BM+ DLBCL showed absence of 7q gain. Copyright © 2010 John Wiley & Sons, Ltd.Keywords
This publication has 23 references indexed in Scilit:
- Single nucleotide polymorphism‐arrays provide new insights in the pathogenesis of post‐transplant diffuse large B‐cell lymphomaBritish Journal of Haematology, 2010
- Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survivalBlood, 2009
- Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphomaNature, 2009
- Bayesian DNA copy number analysisBMC Bioinformatics, 2009
- The potential of copy number gains and losses, detected by array-based comparative genomic hybridization, for computational differential diagnosis of B-cell lymphomas and genetic regions involved in lymphomagenesisHaematologica, 2009
- Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of todays knowledgeLeukemia, 2008
- Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathwaysProceedings of the National Academy of Sciences of the United States of America, 2008
- Revised Response Criteria for Malignant LymphomaJournal of Clinical Oncology, 2007
- The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOPBlood, 2006
- The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvementEuropean Journal of Haematology, 2006